Targeted attack on ovarian cancer halted before launch
NCT ID NCT07060365
Summary
This early-stage trial aimed to test a new, targeted drug called saruparib for women with advanced or recurrent ovarian cancer who have specific genetic changes (BRCA mutations). The goal was to see if the drug was safe and showed early signs of shrinking tumors before planned surgery. The study was withdrawn by the sponsor before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Barcelona, 08028, Spain
Conditions
Explore the condition pages connected to this study.